<qa>  What is the goal of the study?This is an open-label, Phase IV, multicenter, randomized, two-period cross-over study to compare the efficacy and safety of Panzytrat 25,000 to Kreon 25,000 in participants aged 7 years and older suffering from CF and EPI. The study consists of a qualification phase 5 to 15 days; two treatment periods of 14 days each plus a 3-day window if needed and a 3-day stool collection will be performed from Days 12 to 15. 